Back

Early experience optimizing immunosuppressive use and monitoring in MyPEAK-1, a first-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Advanced phenotyping and risk stratification in cardiomyopathies and myocarditis Hypertrophic Cardiomyopathy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Milind Desai

Cleveland Clinic, Cleveland (United States of America)

6 More presentations in this session

Presentation thumbnail
Clinical presentation and prognostic impact of eosinophilic myocarditis associated to eosinophilic granulomatosis with polyangiitis
Doctor S. Ghidini (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Native T1 for diagnosis and risk prediction in amyloid transthyretin cardiomyopathy
Doctor A. Aimo (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Favorable effect of aficamten on left atrial mechanics in obstructive hypertrophic cardiomyopathy: insights from the SEQUOIA-HCM trial
Doctor Y. Hamatani (Boston, US)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance-based phenotyping, genetic architecture, and outcomes in dilated and non-dilated left ventricular cardiomyopathy
Ms A. Heymans (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Staging classification of transthyretin cardiac amyloidosis based on the extent of cardiac damage at echocardiography: a large multicentric Registry.
Doctor D. Tomasoni (Brescia, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Advanced phenotyping and risk stratification in cardiomyopathies and myocarditis
Video

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Session
Tailoring therapeutics for cardiomyopathies
thumbnail
Congress Session
Advances in cardiomyopathies
thumbnail
Congress Presentation
Targets for gene therapy in heart failure and cardiomyopathies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources